Diabetic macular edema: Correlations with available diabetes therapies evidence across a qualitative review of published literature from MEDLINE and EMBASE

Drug Safety

Volumn 33, Issue 8, 2010, Pages 643-652

  Merante, Domenico ^a   Menchini, Francesca ^b   Truitt, Kenneth E ^c   Bandello, Francesco M ^d  

^a DAIICHI SANKYO CO   (Japan)

^b UNIVERSITY OF UDINE   (Italy)

^c DAIICHI SANKYO INC   (United States)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

adverse reactions; Diabetes mellitus; Diabetic retinopathy; Diabetic macular oedema; drug induced; Eye disorders; Pioglitazone; Rosiglitazone; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLICLAZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; PIOGLITAZONE; ROSIGLITAZONE; SOMATOMEDIN C; SPIRONOLACTONE;

DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBASE; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LASER COAGULATION; LEG EDEMA; LITERATURE; LOW DRUG DOSE; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; QUALITY CONTROL; REVIEW; VISUAL ACUITY;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; MACULAR EDEMA; MEDLINE; THIAZOLIDINEDIONES;

EID: 77954693403     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11538340-000000000-00000     Document Type: Review

References (49)

1. World Health Organization. The world health report 2002 [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs312/en/index. html [Accessed 2010 May 5]
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31
3. Vitale S, Maguire MG, Murphy RP, et al. Clinically significant macular edema in type I diabetes: incidence and risk factors. Ophthalmology 1995; 102 (8): 1170-6
4. Early Treatment Diabetic retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy study report number 1. Arch Ophthalmol 1985; 103 (12): 1796-806
5. Friedman EA. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care 1999; 22 Suppl. 2: B65-71
6. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-67
7. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks free pathways of hyperglycaemic damage. Nature 2000; 404: 787-90
8. Ways DK, Sheetz MJ. The role of protein kinase C in the development of the complication of diabetes. Vitam Horm 2000; 60: 149-93
9. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 2000; 77 Suppl.: 113-9
10. Antonetti DA, Lieth E, Barber AJ, et al. Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol 1999; 14: 240-8
11. Lewis H, Abrams GW, Blumenkranz MS, et al. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992; 99: 753-9
12. Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy XV: the long term incidence of macular edema. Ophthalmology 1995; 102: 7-16
13. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy IV: diabetic macular edema. Ophthalmology 1984; 91 (12): 1464-74
14. Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol 2009 Apr; 147 (4): 583-6
15. Avandia/Actos associated with macular edema [online]. Available from URL: http://www.medkb.com/Uwe/Forum. aspx/diabetes-forum/1824/Avandia-Actos- associated-with-Macular-Edema [Accessed 2010 May 5]
16. Ryan Jr EH, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina 2006; 26 (5): 562-70
17. Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Oph-thalmol 2005 Sep; 123 (9): 1273-5
18. Oshitari T, Asaumi N, Watanabe M, et al. Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study. Vasc Health Risk Manag 2008 Oct; 4 (5): 1137-40
19. Liazos E, Broadbent DM, Beare N, et al. Spontaneous resolution of diabetic macular oedema after discontinuation of thiazolidenediones. Diabetic Med 2008 Jul; 25 (7): 860-2
20. Nyssen V, Hautenauven F, Lekeu Hinostroza JP, et al. Diabetic edematous maculopathy associated with rosigli-tazone treatment: report of a case. Bull Soc Belge Ophtal-mol 2009; 313: 39-44
21. EMEA Press Release. EMEA/421484 2005 [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/press/pr/42148405en.pdf [Accessed 2010 May 5]
22. Rosiglitazone: summary of product characteristics last updated on the eMC: 12/04/2010 [online]. Available from URL: http://www.medicines.org.uk/EMC/ medicine/3200/SPC/Avandia [Accessed 2010 May 5]
23. Pioglitazone: Summary of product characteristics last updated on the eMC: 21/04/2010 [online]. Available from URL: http://www.medicines.org.uk/EMC/ history/4236/SPC/Actos [Accessed 2010 May 5]
24. Ambrosius WT, Danis RP, Goff Jr. DC, et al., on behalf of the ACCORD study group. Lack of association between glitazones and macular edema in type 2 diabetes: the ACCORD eye sub-study. Arch Ophthalmol 2010 Mar; 128 (3): 312-8
25. Emoto M, Sato A, Sato Y, et al. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes 2001; 50: 1166-70
26. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256-63
27. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303
28. Kitzmiller JL, Main E, Ward B, et al. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care 1999; 22: 874-5
29. Bhattacharyya A, Vice PA. Insulin lispro, pregnancy, and retinopathy. Diabetes Care 1999; 22 (12): 2101-4
30. Loukovaara S, Immonen I, Teramo KA, et al. R. Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro. Diabetes Care 2003; 26 (4): 1193-8
31. Zib I, Raskin P. Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab 2006; 8 (6): 611-20
32. Meyer CH, Kroll P, Hammes HP. Does insulin glargin (lantus) lead to a progression in diabetic retinopathy? Klin Monatsbl Augenheilkd 2005; 222 (4): 353-4
33. Davis MD, Beck RW, Home PD, et al. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin. Exp Clin Endocrinol Diabetes 2007; 115 (4): 240-3
34. Rosenstock J, Fonseca V, McGill JB, et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia 2009 Sep; 52 (9): 1778-88
35. Tatti P, Arrigoni F, Longobardi A, et al. Retrospective analysis of rosiglitazone and macular edema in patients with type 2 diabetes mellitus. Clin Drug Invest 2008; 28 (5): 327-33
36. Glitazone-associated macular edema. Pharmacist Lett/Prescriber Lett 2006; 22: 220-5
37. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26: 2653-64
38. Porta M, Bandello F. Diabetic retinopathy: a clinical update. Diabetologia 2002; 45: 1617-34
39. The UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
40. Do DV, Shah SM, Sung JU. Persistent diabetic macular edema is associated with elevated hemoglobin A1C. Am J Ophthalmol 2005; 139: 620-3
41. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiological Study of Diabetic Retinopathy XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105: 1801-15
42. Uçgun NI, Yildirim Z, Kiliç N, et al. The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients. Ann N Y Acad Sci 2007; 110: 213-7
43. Gupta A, Gupta V, Thapar S, et al. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004; 137: 675-82
44. Simo' R, Hernandez C. Fenofibrate for diabetic retinopathy. Lancet 2007; 370 (9600), 17: 1667-8
45. Awata T, Neda T, Iizuka H, et al. Endothelial nitrix oxide synthase gene is associated with diabetic macular edema in type 2 diabetes. Diabetes Care 2004; 27 (9): 2184-90
46. Lee SJ, Choi MG. Association of manganese superoxide dismutase gene polymorphism (V16A) with diabetic ma-cular edema in Korean type 2 diabetic patients. Metabolism 2006; 55: 1681-8
47. Tumanan-Mendoza BA, Dans AL, Villacin LL, et al. Dechallenge and rechallenge method showed different incidences of cough among four ACE-Is. J Clin Epidemiol 2007; 60 (6): 547-53
48. Masaki K, Shigeru K. Role of the post-marketing surveillance which shoulders proper use of pharmaceutical products: importance of cooperation between physician and pharmacist in the post-marketing surveillance. J Pract Pharm 2003; 54 (1): 15-9
49. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281: 824-9